Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.42
+0.130010.08%
Post-market: 1.430.0100+0.70%19:25 EDT
Volume:3.48M
Turnover:4.93M
Market Cap:310.60M
PE:-1.16
High:1.47
Open:1.30
Low:1.29
Close:1.29
Loading ...

Allogene Therapeutics (ALLO) Receives a Hold from Bernstein

TIPRANKS
·
06 Jun

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
02 Jun

Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler

TIPRANKS
·
02 Jun

BRIEF-Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO

Reuters
·
01 Jun

Allogene Therapeutics Inc - Single Dose of Allo-316 Achieves 31% Response Rate

THOMSON REUTERS
·
01 Jun

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at Asco

THOMSON REUTERS
·
01 Jun

Allogene Therapeutics Inc. to Participate in Goldman Sachs Annual Global Healthcare Conference

Reuters
·
23 May

Allogene Therapeutics Unveils Promising Results for ALLO-316 in Kidney Cancer and Cema-Cel in Lymphoma at ASCO 2025

Reuters
·
23 May

Binance Wallet's new TGE ALLO (RWA) concludes oversubscribed by over 143 times

Blockbeats
·
22 May

Binance Wallet's new TGE ALLO (RWA) is now open for investment

Blockbeats
·
22 May

Binance Alpha ALLO (RWA) TGE Threshold is 195 points

Blockbeats
·
22 May

Binance Wallet will list the ALLO TGE

Blockbeats
·
21 May

Allogene Therapeutics Inc : Citigroup Cuts Target Price to $4 From $8

THOMSON REUTERS
·
15 May

Allogene Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
15 May

Allogene Therapeutics Price Target Maintained With a $10.00/Share by RBC Capital

Dow Jones
·
14 May

Piper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
14 May

Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital

TIPRANKS
·
14 May

U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth

Reuters
·
14 May

Allogene Therapeutics Inc : Baird Cuts Target Price to $9 From $12

THOMSON REUTERS
·
14 May

Allogene Therapeutics Inc : Truist Securities Cuts Target Price to $10 From $14

THOMSON REUTERS
·
14 May